TITLE

Action Needed to Improve Timeliness and Enhance Scope of FDA's Debarment and Disqualification Processes for Medical Product Investigators

AUTHOR(S)
Crosse, Marcia
PUB. DATE
October 2009
SOURCE
GAO Reports;10/22/2009, preceding p1
SOURCE TYPE
Government Documents
DOC. TYPE
Article
ABSTRACT
The article reports on the study conducted by the U.S. Government Accountability Office (GAO) on the action needed to improve the Food and Drug Administration's (FDA) timely completion of debarment and disqualification processes clinical investigators. It states that investigators who have engaged in wrongful conduct such as presenting fraudulent data can be debarred or disqualified. GAO recommends that the FDA commissioner should ensure the timely completion of the proceedings.
ACCESSION #
45033197

 

Related Articles

  • FDA beefs up rules governing investigator debarment actions. McCarthy, Mark // Medical Device Daily;4/20/2011, Vol. 15 Issue 76, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) has a new rule on debarment of clinical investigators (CI). According to the new rule, any CI banned from receiving a drug, biologic or device will now be allowed from all three kinds of trials. It is noted that the ban is...

  • Food and Drug Administration: Employee Performance Standards for the Timely Review of Medical Product Applications.  // GAO Reports;5/18/2012, p1 

    The article focuses on a report issued by the U.S. Government Accountability Office regarding the standards that the U.S. Food and Drug Administration (FDA) consider to assess the performance of its employees. It mentions that the processing of medical product applications depends on the FDA...

  • FDA Update.  // Pharmaceutical Representative;May2010, Vol. 40 Issue 5, p11 

    The article focuses on a report issued by the U.S. Government Accountability Office (GAO) concerning the strategic planning and management of the Food and Drug Administration (FDA).

  • WEEK IN WASHINGTON.  // BioWorld Insight;2/18/2014, Vol. 22 Issue 7, p6 

    The article offers information on the role of the U.S. Food and Drug Administration for missing out the opportunities to mitigate and proactively prevent drug shortages in the U.S., according to the reports of the U.S. Government Accountability Office (GAO).

  • FDA safety effort necessary.  // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p10 

    The article reports on the U.S. Government Accountability Office (GAO) study on the need for the Food and Drug Administration (FDA) to develop a comprehensive plan to prepare the Office of Surveillance and Epidemiology (OSE) to take over additional regulatory authorities from the Office of New...

  • FDA Questioned by Other Feds on High-Risk Devices. Reed, Vita // Orange County Business Journal;4/25/2011, Vol. 34 Issue 17, p65 

    The article reports that the approval of U.S. Food and Drug Administration (FDA) to certain high-risk medical devices such as pacemakers and hip joints, has been criticized by the Government Accountability Office (GAO), which states that the high-risk devices are approved without sufficient...

  • Continued Opportunities Exist for FDA and OPM to Improve Oversight of Recruitment, Relocation, and Retention Incentives. Goldenkoff, Robert N. // GAO Reports;2/22/2010, preceding p1 

    The article presents a study done by the United States Accountability Office (GAO) which aims to know the extent to which the Food and Drug Administration (FDA) is linking its use of employee recruitment, relocation and retention (3R) incentives to its human capital approaches in addressing...

  • NATIONAL CORD BLOOD INVENTORY: Practices for Increasing Availability for Transplants and Related Challenges.  // GAO Reports;10/7/2011, preceding p1 

    The article presents a report from the U.S. Government Accountability Office (GAO) regarding the inventory of national cord blood. It notes that the agency has examined practices that will increase the banking of cord blood units while examining the ways using efficient cord blood banking....

  • News in brief.  // Nature Medicine;Dec2008, Vol. 14 Issue 12, p1296 

    The article offers information on policies related to medicine. The U.S. Government Accountability office refers to serious security problems in two laboratories given clearances to study deadly pathogens. The Laboratory Corporation of America agreed to stop selling unapproved tests for ovarian...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics